MmpL3 a potential new target for development of novel anti-tuberculosis drugs

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 3, 2014, Pages 247-256

  Rayasam, Geetha Vani ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

Drug discovery; Drug target; Mycolic acid; Transporters

Indexed keywords

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG DESIGN; HUMANS; MEMBRANE TRANSPORT PROTEINS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84894136887     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.859677     Document Type: Review

References (79)

1. WHO TB Report 2012. Available from: http://www.who.int/tb/country/en/ index. html
2. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375: 1830-43
3. Udwadia ZF, Amale R, Ajbani K, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012;54(4): 579-81
4. Phillips L. Infectious disease: TB's revenge. Nature 2013;493: 14-16
5. Available from: http://www.who.int/tb/features-archive/new-treatment- guidelines-may2010/en/index.html
6. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2010;205:S241-9
7. Goldberg DE, Siliciano RF, Jacobs WR. Outwitting evolution: fighting drugresistant TB, malaria, and HIV. Cell 2012;148(6): 1271-83
8. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Available from: http://whqlibdoc.who. int/publications/2011/9789241501583-eng. pdf
9. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis - current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012;205(Suppl 2):S228-40
10. Ginsberg AM. Drugs in development for tuberculosis. Drugs 2010;70(17): 2201-14
11. Rivers EC, Mancera RL. New antituberculosis drugs with novel mechanisms of action. Curr Med Chem 2008;15(19): 1956-67
12. Zhang Y, Yew WW, Barer MR. Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 2012;56(5): 2223-30
13. Krishnan N, Robertson BD, Thwaites G. The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2010;90(6): 361-6
14. WHO TB/HIV Report. Available from: http://www.who.int/tb/challenges/hiv/ factsheets/en/index.html
15. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393(6685): 537-44
16. Hett EC, Rubin EJ. Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev 2008;72(1): 126-56
17. Favrot L, Ronning DR. Targeting the mycobacterial envelope for tuberculosis drug development. Expert Rev Anti Infect Ther 2012;10(9): 1023-36
18. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinburgh) 2003;83: 91-7
19. Takayama K, Wang C, Besra GS. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin Microbiol Rev 2005;18(1): 81-101 • Extensive review of the mycolic acid biosynthesis.
20. Kaur D, Guerin ME, Škovierová H, et al. Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis. Adv Appl Microbiol 2009;69: 23-78
21. Hoffmann C, Leis A, Niederweis M, et al. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc Natl Acad Sci USA 2008;105(10): 3963-7
22. Verschoor JA, Baird MS, Grooten J. Towards understanding the functional diversity of cell wall mycolic acids of Mycobacterium tuberculosis. Prog Lipid Res 2012;51(4): 325-39
23. Barkan D, Hedhli D, Yan HG, et al. Mycobacterium tuberculosis lacking all mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice. Infect Immun 2012;80(6): 1958-68
24. Vander Beken S, Al Dulayymi JR, Naessens T, et al. Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern. Eur J Immunol 2011;41(2): 450-60
25. Yuan Y, Zhu Y, Crane DD, Barry CE III. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis. Mol Microbiol 1998;29(6): 1449-58
26. Dubnau E, Chan J, Raynaud C, et al. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol Microbiol 2000;36(3): 630
27. Schweizer E, Hofmann J. Microbial type I fatty acid synthases (FAS): major players in a network of cellular FAS systems. Microbiol Mol Biol Rev 2004;68(3): 501-17
28. Bhatt A, Molle V, Besra GS, et al. The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development. Mol Microbiol 2007;64(6): 1442-54
29. Zhang YM, Lu YJ, Rock CO. The reductase steps of the type II fatty acid synthase as antimicrobial targets. Lipids 2004;39(11): 1055-60
30. Schaeffer ML, Agnihotri G, Volker C, et al. Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB. J Biol Chem 2001;276(50): 47029-37
31. Sacco E, Covarrubias AS, O'Hare HM, et al. The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2007;104(37): 14628-33
32. Portevin D, De Sousa-D'Auria C, Houssin C, et al. A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms. Proc Natl Acad Sci USA 2004;101(1): 314-19
33. Schroeder EK, de Souza N, Santos DS, et al. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr Pharm Biotechnol 2002;3(3): 197-225
34. Marrakchi H, Lanéelle G, Quémard A. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology 2000;146(Pt 2): 289-96
35. Grzegorzewicz AE, Korduláková J, Jones V, et al. A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J Biol Chem 2012;287(46): 38434-41
36. Belardinelli JM, Morbidoni HR. Mutations in the essential FAS II betahydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii. Mol Microbiol 2012;86(3): 568-79
37. Freundlich JS, Wang F, Vilchèze C, et al. Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem 2009;4(2): 241-8
38. Parikh SL, Xiao G, Tonge PJ. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 2000;39(26): 7645-50
39. Kremer L, Douglas JD, Baulard AR, et al. Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J Biol Chem 2000;275(22): 16857-64
40. Betts JC, McLaren A, Lennon MG, et al. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47(9): 2903-13
41. Belisle JT, Vissa VD, Sievert T, et al. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997;276(5317): 1420-2
42. Ronning DR, Klabunde T, Besra GS, et al. Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat Struct Biol 2000;7(2): 141-6
43. Warrier T, Tropis M, Werngren J, et al. Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. Antimicrob Agents Chemother 2012;56(4): 1735-43
44. Varela C, Rittmann D, Singh A, et al. MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria. Chem Biol 2012;19(4): 498-506 • Genetic evidence to suggest MmpL3 as a transporter of mycolic acids.
45. Saier MH Jr, Paulsen IT. Phylogeny of multidrug transporters. Semin Cell Dev Biol 2001;12(3): 205-13
46. Kim EH, Nies DH, McEvoy MM, Rensing C. Switch or funnel: how RNDtype transport systems control periplasmic metal homeostasis. J Bacteriol 2011;193(10): 2381-7
47. Domenech P, Reed MB, Barry CE III. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 2005;73(6): 3492-501 • Article demonstrating essentiality of MmpL3 to Mtb.
48. Tekaia F, Gordon SV, Garnier T, et al. Analysis of the proteome of Mycobacterium tuberculosis in silico. Tuber Lung Dis 1999;79(6): 329-42
49. Converse SE, Mougous JD, Leavell MD, et al. MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium tuberculosis virulence. Proc Natl Acad Sci USA 2003;100(10): 6121-6
50. Domenech P, Reed MB, Dowd CS, et al. The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem 2004;279(20): 21257-65
51. Pérez J, Garcia R, Bach H, et al. Mycobacterium tuberculosis transporter MmpL7 is a potential substrate for kinase PknD. Biochem Biophys Res Commun 2006;348(1): 6-12
52. Tullius MV, Harmston CA, Owens CP, et al. Discovery and characterization of a unique mycobacterial heme acquisition system. Proc Natl Acad Sci USA 2011;108(12): 5051-6 • Implication of MmpL3 and 11 in heme transport.
53. Owens CP, Chim N, Graves AB, et al. The mycobacterium tuberculosis secreted protein Rv0203 transfers Heme to membrane proteins MmpL3 and MmpL11. J Biol Chem 2013;288(30): 21714-28 • Evidence for heme binding by MmpL3.
54. Owens CP, Chim N, Goulding CW. Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target. Fut Med Chem 2013;5(12): 1391-403
55. Grzegorzewicz AE, Pham H, Gundi VA, et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 2012;8(4): 334-41 • First paper demonstrating involvement of MmpL3 in mycolic acid transport.
56. North EJ, Scherman MS, Bruhn DF, et al. Design, synthesis and antituberculosis activity of 1-adamantyl-3- heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg Med Chem 2013;21(9): 2587-99
57. Deidda D, Lampis G, Fioravanti R, et al. Bactericidal activities of the pyrrole derivative BM212 against multidrugresistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 1998;42(11): 3035-7
58. La Rosa V, Poce G, Canseco JO, et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 2012;56(1): 324-31 • Identification of target for BM212.
59. Poce G, Bates RH, Alfonso S, et al. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One 2013;8(2):e56980
60. Jia L, Tomaszewski JE, Hanrahan C, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005;144: 80-7
61. Tahlan K, Wilson R, Kastrinsky DB, et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012;56(4): 1797-809 • Identification of mechanism of action of SQ109.
62. Stanley SA, Grant SS, Kawate T, et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol 2012;7(8): 1377-84 • Identification of MmpL3 and DprE1 inhibitors from whole cell screening.
63. Remuiñán MJ, Pérez-Herrán E, Rullás J, et al. Tetrahydropyrazolo[1,5-a] Pyrimidine-3-Carboxamide and NBenzyl- 6',7'-Dihydrospiro[ Piperidine- 4,4'-Thieno[3,2-c]Pyran] Analogues with Bactericidal Efficacy against Mycobacterium tuberculosis Targeting MmpL3. PLoS One 2013;8(4):e60933 • Two novel inhibitors of MmpL3 showing in vivo efficacy.
64. Murakami S, Nakashima R, Yamashita E, Yamaguchi A. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 2002;419(6907): 587-93
65. Elkins CA, Nikaido H. Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops. J Bacteriol 2002;184(23): 6490-8
66. Yu EW, McDermott G, Zgurskaya HI, et al. Structural basis of multiple drugbinding capacity of the AcrB multidrug efflux pump. Science 2003;300(5621): 976-80
67. Yu EW, Aires JR, Nikaido H. AcrB multidrug efflux pump of Escherichia coli: composite substrate-binding cavity of exceptional flexibility generates its extremely wide substrate specificity. J Bacteriol 2003;185(19): 5657-64
68. Cole ST. Infectious diseases: transporter targeted in tuberculosis. Nat Chem Biol 2012;8(4): 326-7
69. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013;12(5): 388-404 • Review article covering novel targets like MmpL3 and DprE1.
70. Jain M, Cox JS. Interaction between polyketide synthase and transporter suggests coupled synthesis and export of virulence lipid in M. tuberculosis. PLoS Pathog 2005;1(1):e2
71. Harrison C. Hitting the tuberculosis wall. Nat Rev Drug Discov 2013;12: 578-9
72. Christophe T, Jackson M, Jeon HK, et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 2009;5(10):e1000645
73. Manina G, Pasca MR, Buroni S, et al. Decaprenylphosphoryl-b-D-ribose 2'- epimerase from Mycobacterium tuberculosis is a magic drug target. Curr Med Chem 2010;17(27): 3099-108
74. Magnet S, Hartkoorn RC, Székely R, et al. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb) 2010;90(6): 354-60
75. Crellin PK, Brammananth R, Coppel RL. Decaprenylphosphoryl-beta- D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis. PLoS One 2011;6(2):e16869
76. Batt SM, Jabeen T, Bhowruth V, et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc Natl Acad Sci USA 2012;109(28): 11354-9
77. Trefzer C, Škovierová H, Buroni S, et al. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-beta- D-ribofuranose 2'-oxidase DprE1. J Am Chem Soc 2012;134(2): 912-15
78. Wang F, Sambandan D, Halder R, et al. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci USA 2013;110(27):E2510-17
79. Makarov V, Manina G, Mikusova K, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009;324(5928): 801-4